RETRATRUTIDE - GLP-1/GIP/GCG

Retatrutide is designed to revolutionize the treatment of obesity and type 2 diabetes. By simultaneously targeting GLP-1, GIP, and glucagon receptors, Retatrutide offers a comprehensive approach to weight management and blood sugar control1. Clinical trials have shown impressive results, with patients experiencing up to 17.5% mean weight reduction over 24 weeks. Plus, with its convenient once-weekly injection, Retatrutide is designed for ease of use and improved patient compliance.